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CORONARY ARTERY DISEASE (CAD)
1. Percutaneous coronary intervention in stable angina 
(ORBITA): A double-blind, randomised controlled trial
ORBITA (Objective Randomized Blinded Investigation 
With Optimal Medical Therapy of Angioplasty in Stable 
Angina) is a blinded; multicenter randomized (1:1) trial of 
percutaneous coronary intervention (PCI) vs. a placebo pro-
cedure for angina relief that was done at five (5) centers in 
the UK. All patients had severe (≥70%) stenosis in a major 
epicardial coronary artery and underwent an intensive 6-week 
medication optimization period, including up-titration from 
about 1 to 3 medications, with multiple weekly physician 
consultations. Afterwards they were randomized in the cath-
eterization laboratory to PCI or a sham procedure. The study 
showed that there was no significant difference on the primary 
endpoint, incremental improvement in exercise treadmill time 
(PCI, 28s; sham surgery, 12s). Groups also did not differ in 
improvements in time to 1-mm ST depression, peak oxygen 
uptake, Seattle Angina Questionnaire physical function or 
angina frequency, and quality-of-life score. PCI was associated 
with a small, significantly greater improvement in ischemia, 
as measured by wall-motion index score on Dobutamine stress 
echocardiography (difference,–0.09). This study emphasizes 
the importance of optimum anti-anginal medication, which 
should continue to be the first-line therapy. As the authors note, 
the findings do not imply that patients should never undergo 
PCI for stable angina and do not apply to acute coronary 
syndromes (ACS), for which PCI has well-proven benefits. 
Al-Lamee R et al. Lancet 2018;391:31-40. doi: 10.1016/
S0140-6736(17)32714-9. Epub 2017 Nov 2.
2. PCI Strategies in Patients with Acute Myocardial 
Infarction and Cardiogenic Shock
Culprit-Shock (Culprit Lesion Only PCI Versus Multivessel 
PCI in Cardiogenic Shock) is a multicenter randomized trial 
in which 706 patients who had multivessel disease (MVD), 
acute myocardial infarction (AMI), and cardiogenic shock 
randomly assigned to one of two initial revascularization 
strategies: percutaneous coronary intervention (PCI) of the 
culprit lesion only, with the option of staged revascularization 
of non-culprit lesions, or immediate MV PCI. The trial showed 
a significant clinical benefit of a culprit-lesion-only strategy 
with a reduction in the primary end point of 30-day mortality 
or severe renal failure requiring renal replacement therapy 
(45.9% culprit-lesion-only PCI vs. 55.4% immediate MV PCI 
group; p=0.01), which was driven mainly by an absolute 8.2% 
reduction in 30-day mortality (43.3% versus 51.5%; p=0.03). 
However, the time to hemodynamic stabilization, the risk of 
catecholamine therapy and the duration of such therapy, the 
levels of troponin T and creatine kinase (CK), and the rates 
of bleeding and stroke did not differ significantly between the 
two groups. Holger Thiele et al. N Engl J Med 2017; 377:2419-
2432. doi: 10.1056/NEJMoa1710261. Epub 2017 Oct 30.
3. Double Kissing Crush Versus Provisional Stenting 
for Left Main Distal Bifurcation Lesions: DKCRUSH-V 
Randomized Trial
The Double Kissing (DK) Crush planned 2-stent technique 
has been shown to improve clinical outcomes in non-LM 
bifurcations compared with Provisional Stenting (PS) and in 
Left Main (LM) bifurcations compared with Culotte stent-
ing technique, but has never been compared with PS in LM 
bifurcation lesions. In this multicenter (26 centers in 5 coun-
tries) randomized trial, percutaneous coronary intervention 
(PCI) of true distal LM bifurcation lesions (Medina 1.1.1 or 
0.1.1) using a planned DK crush 2-stent strategy resulted in a 
lower rate of target lesion failure (TLF) at 1 year than the PS 
strategy (5,0% vs. 10.7%, p=0.02). Compared with PS, DK 
crush also resulted in lower rates of target vessel myocardial 
infarction (2.9% vs. 0.4%; p=0.03) and definite or probable 
stent thrombosis (3.3% vs. 0.4%; p=0.02). Clinically driven 
target lesion revascularization (7.9% vs. 3.8%; p=0.06) and 
angiographic restenosis within the LM complex (14.6% vs. 
7.1%; p=0.10) also tended to be less frequent with DK crush 
compared with PS. However we must point out that there was 
no significant difference in cardiac death between the groups. 
Chen SL, et al. J Am Coll Cardiol 2017;70:2605-2617. doi: 
10.1016/j.jacc.2017.09.1066. Epub 2017 Oct 30.
STRUCTURAL HEART DISEASE (SHD)
1. Surgical or Transcatheter Aortic-Valve Replacement 
in Intermediate-Risk Patients
SURTAVI (SUrgical Replacement and Transcatheter Aortic 
Valve Implantation) is a multicenter (26 centers in 5 countries) 
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randomized trial, which by using Bayesian analytical methods 
(with a margin of 0.07), among 1746 severe AS patients at 
intermediate surgical risk (Society of Thoracic Surgeons Pre-
dicted Risk of Mortality, 4.5±1.6%) showed that Transcatheter 
Aortic-Valve Replacement (TAVR) by using the self-expanding 
device of Medtronic is non-inferior to SAVR, confirming ear-
lier results with the balloon-expandable device of Edwards in 
PARTNER 2A study. Moreover, surgery was associated with 
higher rates of acute kidney injury (AKI), atrial fibrillation 
(AF), and transfusion requirements, whereas TAVR had higher 
rates of residual aortic regurgitation (AR) and need for pace-
maker implantation (PPI). A limitation of the study was the 
absence of long-term follow-up since a 24-month end-point 
analysis provides incomplete information about the life cycle 
of TAVR versus surgical bio-prostheses and that the trial was 
totally funded by Medtronic. However, the findings of this and 
PARTNER 2A studies will likely lead to an FDA indication 
for TAVR in intermediate surgical risk patient population. 
Reardon MJ et al. N Engl J Med 2017;376:1321-1331. doi: 
10.1056/NEJMoa1700456. Epub 2017 Mar 17.
2. In-hospital outcomes of transcatheter (TAVR) versus 
surgical aortic valve replacement (SAVR) in end stage 
renal disease (ESRD)
In this propensity matched analysis of End Stage Renal 
Disease (ESRD) patients on hemodialysis (HD) coming from 
National Inpatient Sample (NIS) undergoing Transcatheter 
Aortic-Valve Replacement (TAVR) (n = 328) or surgery (SAVR) 
(n = 697) between 2012 and 2014 was shown that regardless 
the treatment modality, patients with AS on HD have high 
in-hospital mortality. TAVR and SAVR have comparable in-
hospital mortality rate however, TAVR was associated with 
shorter length of stay (LOS) (8 vs. 14 days, p <0.001), lower 
hospitalization cost ($276,448 vs. $364,280, p=0.01), lower 
in-hospital complications (60.6% vs. 76%, p=0.003), and higher 
rate of home discharge (31.4% vs. 17.7%, p=0.004) vs. SAVR. 
Alkhalil A, et al. Catheter Cardiovasc Interv 2018;92:757-765. 
doi: 10.1002/ccd.27433. Epub 2017 Nov 24.
3. Outcomes With Transcatheter Mitral Valve Repair in 
the United States: An STS/ACC TVT Registry Report
This is an analysis of the commercial experience in the 
United States (US) regarding the transcatheter mitral valve 
repair (TMVR) treatment of mitral regurgitation (MR). The 
study population consisted of 2,952 patients treated at 145 
Centers between November 2013 and September 2015. In 
1,867 patients, data were linked to patient-specific Centers 
for Medicare and Medicaid Services administrative claims 
for analyses. The acute procedure success was 91.8%. Among 
the patients with Centers for Medicare and Medicaid Services 
linkage data, the mortality at 30 days and at 1 year was 5.2% 
and 25.8%, respectively, and repeat hospitalization for heart 
failure (HF) at 1 year occurred in 20.2%. Variables associated 
with mortality or re-hospitalization for HF after multivariate 
adjustment were: increasing age, lower baseline left ven-
tricular ejection fraction (LVEF), worse post-procedural MR, 
moderate or severe lung disease, dialysis, and severe tricuspid 
regurgitation. These findings demonstrate that commercial 
TMVR is effective and safe procedure. Additionally it may 
help to determine which patients have favorable long-term 
outcomes with this therapy. Sorajja P, et al. J Am Coll Cardiol 
2017;70:2315-2327.doi: 10.1016/j.jacc.2017.09.015.
4. Long-Term Outcomes of Patent Foramen Ovale 
Closure or Medical Therapy after Stroke
The RESPECT trial is a multicenter, randomized, open-label 
blinded trial, which enrolled 980 adult patients (between ages 
18 and 60 years old) with cryptogenic ischemic stroke (CIS). 
It was shown that Patent Foramen Ovale (PFO) closure with 
the Amplatzer PFO Occluder is superior to medical manage-
ment (aspirin, warfarin, clopidogrel, or aspirin combined with 
extended-release dipyridamole) in reducing recurrent strokes in 
patients with presumed CIS and evidence of a PFO on long-term 
follow-up (>5 years). These results are similar to those noted 
in the REDUCE and CLOSE trials. An interesting observation 
was that nearly one third of strokes thought to be cryptogenic 
likely had another underlying mechanism. In addition, venous 
thromboembolism (which comprised events of pulmonary 
embolism and deep-vein thrombosis) was more common in the 
PFO closure group than in the medical-therapy group. Therefore, 
according to FDA a strong collaboration between neurologists 
and cardiologists is required to exclude other causes of strokes. 
Saver JL et al, for the RESPECT Investigators* N Engl J Med 
2017;377:1022-1032. doi: 10.1056/NEJMoa1610057.
HEART FAILURE
1. CASTLE-AF: Catheter Ablation vs. Conventional 
Therapy For Patients With AFib and LV Dysfunction
This trial included 397 patients with symptomatic parox-
ysmal or persistent atrial fibrillation (AF) and a left ventricular 
ejection fraction (LVEF) of ≤35% who were randomized to re-
ceive radiofrequency catheter ablation or conventional medical 
treatment. Moreover, all patients had NYHA class II, III, or IV 
heart failure (HF) and an implantable cardioverter defibrillator 
(ICD) with Home Monitoring capability. Results showed the 
composite of all-cause mortality and unplanned hospitalization 
for worsening HF (primary endpoint) was significantly lower 
in the ablation group (28.5%) compared to the control group 
(44.6%) over a median follow-up period of 37.8 months. How-
ever, there are certain limitations: (1) The quality of the rate 
control in the pharmacological group has not been published 
and there were still active attempts to maintain sinus rhythm in 
this group. (2) AV nodal ablation was rarely used in CASTLE-
AF study. Indeed at 5 years, 20% of the patients randomized to 
pharmacological rate control were still in sinus rhythm and only 
56% had persistent AF. (3) There were potentially significant 
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differences in patient characteristics between the groups, with 
a greater incidence of diabetes and ischemic cardiomyopathy. 
In addition, patients with an LVEF <25% appeared to have 
no benefit from ablation. Therefore, AF ablation seems to be 
beneficial in a highly selected group of patients with AF and 
severe HF in whom antiarrhythmic drugs are not tolerated or 
ineffective. We expect the results from CABANA and EAST 
AFNET 4 trial for further details in this interesting topic. Nassir 
F. Marrouche, MD (PI). CASTLE-AF trial presented on Aug. 
27 at the ESC Congress 2017 in Barcelona.
ATRIAL FIBRILLATION
1. 2017 ACC Expert Consensus Decision Pathway for 
Periprocedural Management of Anticoagulation in 
Patients With Non-valvular Atrial Fibrillation: A Report 
of the American College of Cardiology Clinical Expert 
Consensus Document Task Force
This is an expert consensus document, which assists clini-
cians to quickly and effectively decide which peri-procedural 
management of anticoagulation for patients with non-valvular 
atrial fibrillation (NVAF) are appropriate. The following key 
points are important:
 - When considering if interrupting anticoagulation is neces-
sary, clinicians should consider the type of oral anticoagu-
lant (vitamin K antagonists [VKAs] with a long half-life vs. 
direct oral anticoagulants [DOACs] with a shorter half-life), 
the patient’s bleeding risk, the procedural bleeding risk, 
and any additional clinical information.
 - Some procedures (e.g., implantation of pacemakers or 
ICD) have demonstrated lower bleeding risks when VKA 
therapy is continued uninterrupted rather than interrupted 
and heparin bridging is administered.
 - To assess a patient’s risk of bleeding, elements of the 
HAS-BLED score (hypertension, abnormal liver or renal 
function, prior stroke, prior major bleeding or anemia, 
labile INR for VKA patients, age >65 years, concomitant 
use of antiplatelet agents or nonsteroidal anti-inflammatory 
drugs) should be assessed along with any recent bleeding 
events (within 3 months), platelet abnormalities, elevated 
INR values for VKA patients, and any prior procedural 
bleeding history.
 - Do not interrupt VKA therapy in patients undergoing 
procedures with no clinically important risk or low risk 
of bleeding and no patient-related factors that increase 
bleeding risk.
 - When interrupting VKA therapy, the VKA should be 
stopped 3-4 days prior to procedure (for INR 1.5-1.9), 
5 days prior to procedure (for INR 2.0-3.0), or at least 5 
days prior to procedure (for INR >3.0). The INR should 
be re-checked within 24 hours before the procedure.
 - Use of bridging parenteral heparin should only be con-
sidered in the following two scenarios: (1) VKA-treated 
patients at high risk of stroke or systemic embolism (>10% 
per year), including those with a CHA2DS2-VASc score 
of 7-9 or a recent (within 3 months) ischemic stroke, or 
(2) VKA-treated patients with a prior stroke or systemic 
embolism (≥3 months previously) who are not at a sig-
nificant peri-procedural bleeding risk.
 - For patients on DOAC therapy who require interruption of 
anticoagulation therapy pre-procedurally, the number of 
doses to be held is determined by the estimated creatinine 
clearance and the procedural bleeding risk. A standard table 
should be referenced for this decision-making process. 
Parenteral heparin bridging is not indicated for DOAC-
treated patients.
 - Before restarting oral anticoagulant therapy, ensure com-
plete hemostasis. Otherwise, VKA therapy can usually be 
restarted within 24h and parenteral heparin bridging (if 
indicated) within 24-72h depending on post-procedural 
bleeding risk. DOAC therapy should not be reinitiated 
before 24-72h post-procedure without any parenteral 
heparin bridging based on post-procedure bleeding risk 
unless the patient cannot tolerate oral therapy.
 - DOAC therapy should not be used in patients undergoing 
mechanical valve replacement. Doherty JU et al. JACC 
2017;69:871-898. doi: 10.1016/j.jacc.2016.11.024. Epub 
2017 Jan 9.
ARTERIAL HYPERTENSION
1. 2017 Guideline for High Blood Pressure in Adults
The new guidelines is the first comprehensive set since 
2003 that addresses a broad spectrum of topics, including BP 
measurement, secondary hypertension, and managing hyper-
tension in patients with comorbidities. But the big changes 
– heavily influenced by results of the SPRINT study – are:
1. Newly defined categories are: 
 - Elevated blood pressure (BP) (systolic BP 120–129mmHg 
and diastolic BP <80mmHg) 
 - Stage 1 hypertension (systolic BP 130–139mmHg or 
diastolic BP 80–89mmHg)
 - Stage 2 hypertension (systolic BP ≥140 mmHg or diastolic 
BP ≥90 mmHg)
2. For people with elevated BP, lifestyle modification is 
recommended.
3. For people with stage 1 hypertension who have known 
atherosclerotic cardiovascular disease (CVD) or 10-year 
cardiovascular risk ≥10% (according to the ACC/AHA 
calculator, which also is used for cholesterol management), 
both lifestyle modification and drug therapy are recom-
mended. Stage 1 patients with <10% 10-year risk should 
pursue lifestyle modification only.
4. All people with Stage 2 hypertension should receive 
medication (in addition to lifestyle modification).
5. The treatment goal for everyone is <130/80 mmHg.
http://www.acc.org/latest-in-cardiology/articles/2017/ 
11/08/11/47/mon-5pm-bp-guideline-aha-2017.
